Search Results

Get ready to stay up-to-date with the latest research, advancements, and news in the field. From the scientist’s view: a conversation with … Chris Tate AI is dreaming up drugs that no one has ever

surprising discovery that β-arrestin can bind GPCRs without receptor activation, to visualizing intermediate states the Symposia GPCR Publication Highlights     Arrestin recognizes GPCRs independently of the receptor state Triple Labeling Resolves a GPCR Intermediate State by Using Three-Color Single Molecule FRET .   A powerful three-color approach captures dynamic receptor states in real time. Whether you're decoding a hidden receptor state or hunting for the next orphan GPCR ligand, we're here

It does mean that stabilizing the receptor's active state through a small molecule, at this specific The receptor samples many states. The active state is, on this account, the conformation in which the largest number of those contacts The active state can be stabilized through a different geometric route, one that does not require the It is that allosteric chemistry has a structural advantage when the goal is stabilizing an active state

Chris Tate co-founded Heptares after reading one paper on a Friday afternoon. . << Back to podcast list Strategic Partner(s) Chris Tate: Thermostabilizing GPCRs for Structural Biology Chris Tate spent years working on membrane proteins that were simply too unstable to study by crystallography ABOUT THE GUEST Chris Tate is a group leader at the MRC Laboratory of Molecular Biology in Cambridge, Chris Tate obtained his Ph.D. from the University of Bristol in 1989 and then moved to the University

Marshall walks through the decade when membrane proteins kept failing to crystallize in detergent, and how Chris Tate's thermostabilization strategy finally made GPCR structures routine, the insight that seeded Heptares Chris Tate's thermostabilization strategy, which introduced stabilizing mutations selected by thermal Chris Tate and Dr. Richard Henderson at the Laboratory of Molecular Biology in Cambridge, UK. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send

<< Back to podcast list Strategic Partner(s) Chris Langmead Chris Langmead is Professor, Deputy Director in drug discovery, particularly in the field of psychiatry, where he has led multiple projects into late Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009). Chris serves on the editorial boards of the British Journal of Pharmacology, ACS Chemical Neuroscience It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send